Variable | Pre-ACCESS, n (%) | Post-ACCESS, n (%) | Change, n (%) | P value |
---|---|---|---|---|
Number of cases, n | 1685 | 1624 | -61 (-4) | - |
Number of cases by priority level, n (%) | <0.0001 | |||
P2 | 187 (11) | 95 (6) | -92 (-49) | |
P3 | 1027 (61) | 768 (47) | -259 (-25) | |
P4 | 471 (28) | 761 (47) | +290 (+62) | |
No. of cases exceeding wait-time targets by priority, n (%) | 0.39 | |||
P2 | 120 (64) | 61 (64) | -59 (-49) | |
P3 | 485 (47) | 297 (39) | -188 (-39) | |
P4 | 122 (26) | 118 (16) | -4 (-3) | |
Median wait-times by priority, days (range) | 0.52 | |||
P2 | 19 (1–215) | 17 (1–55) | -2 (-10) | |
P3 | 27 (0–274) | 23 (0–108) | -4 (-14) | |
P4 | 66 (0–246) | 41 (0–207) | -25 (-37) | |
Type of cancer, n (%) | < 0.0001 | |||
Gastric | 21 (1) | 10 (0.6) | -11 (-52) | |
Endocrine | 238 (14) | 172 (11) | -66 (-28) | |
Genitourinary (excluding prostate) | 228 (14) | 230 (14) | +2 (+1) | |
Gynecological | 350 (21) | 284 (17) | -66 (-19) | |
Head and neck (excluding thyroid) | 154 (9) | 276 (17) | +122 (+79) | |
Lung | 168 (10) | 194 (12) | +26 (+15) | |
Lymph | 2 (0.1) | 3 (0.2) | +1 (+50) | |
Peripheral nervous system | 1 (0.1) | 3 (0.2) | +2 (+200) | |
Prostate | 132 (8) | 105 (6) | -27 (-20) | |
Skin carcinoma1 | 8 (0.5) | 7 (0.4) | -1 (-13) | |
Skin melanoma | 49 (3) | 30 (2) | -19 (-39) |